We examine expression across normal brain and cancers, evaluate survival associations, map the co-expression and interaction contexts, and ask whether loss of OPCML promotes aggressive phenotypes by releasing PI3K–AKT–mTOR signaling. This evidence concerns the gene OPCML and cancer.